ERBB2 and neoplasm: The detection and characterization of targetable genomic alterations that drive tumor growth has prompted an increasing number of guideline-based recommendations for many actionable targets for drug therapy that have demonstrated improved patient outcomes, including EGFR, ALK, ROS1, BRAF, MET, RET, or HER2 [33,53,54].